Business Context and Reporting Period
This Form 8-K is filed by Cytoclonal Pharmaceutics Inc. (not OPKO Health, Inc.) with a report date of April 23, 2001. The filing discloses a change in the registrant's independent certifying accountants.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of auditors.
Material Changes
- Dismissal of Previous Auditor: Richard A. Eisner & Company, LLP was dismissed as independent auditors on April 26, 2001.
- Appointment of New Auditor: Ernst & Young LLP was elected as the new independent accountants effective April 23, 2001.
- Audit History: The previous auditor's reports for fiscal years ended December 31, 2000, and 1999 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- Disagreements: There were no disagreements with the former auditor on accounting principles, practices, or auditing scope/procedures during the two most recent fiscal years or subsequent interim periods.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No reportable events or contingencies were identified in connection with the former auditor's tenure. The registrant confirmed that no consultations regarding accounting principles or audit opinions occurred with the new auditor (Ernst & Young LLP) prior to their appointment.
Investor Verification Checklist
- Verify the reason for the auditor change, as the filing states no disagreements occurred.
- Confirm the identity of the registrant (Cytoclonal Pharmaceutics Inc.) versus the metadata provided (OPKO Health, Inc.).
- Review the letter from Richard A. Eisner & Company, LLP (Exhibit 16.1) to confirm their concurrence with the statements in this report.
- Check subsequent filings for the first financial statements audited by Ernst & Young LLP.